首页 诺瓦瓦克斯医药(usNVAX)-基本信息

诺瓦瓦克斯医药(usNVAX)-基本信息

日报更新时间:04-10 10:00

周报更新时间:04-11 03:39

行情信息

今开价:183.0

最高价:184.97

成交量:2029377.0

昨收价:179.74

最低价:172.22

最新价:175.65

行情图标
概要信息

中文名称:诺瓦瓦克斯医药


英文名称:Novavax


行业:医疗


简介:Novavax, Inc.是一家新型临床阶段生物制药公司,致力于发现、开发和商业化纳米颗粒重组疫苗和佐剂


电话:1-240-2682000


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

诺瓦瓦克斯医药公司的重组纳米颗粒和Matrix-M™佐剂技术是开创性创新的基础,通过安全和有效的疫苗改善全球健康。Novavax的产品线目标是针对呼吸道合胞病毒(“RSV”)、季节性流感、大流行性流感(H1N1、H5N1等)、埃博拉病毒(“EBOV”)等一系列疫苗仍处于研发阶段的传染性疾病,此外,公司还有针对各种传染病的临床前期项目。Novavax在全球拥有多个积极的合作伙伴,包括:Bill & Melinda Gates Foundation、Biomedical Advanced Research and Development Authority (BARDA)、Cadila Pharmaceuticals、LG Life Sciences等。Novavax的临床产品线包括设计用于引起分化的免疫应答的疫苗候选物,具有提供增强的保护的潜力。 其重组纳米颗粒和Matrix™佐剂技术是开创性创新的基础,其具有改善免疫应答和保护免受传统季节性传染病和具有大流行潜力的感染性病原体的威胁的潜力。具体产品线及研发阶段:

交易日期 交易人 职位 类型 交易份额 价格
2019-05-12 Glenn (Gregory M) Officer Buy 1000 5.85
2019-03-26 King (Rachel K) Director Buy 42000 0.53
2019-03-26 King (Rachel K) Director Buy 22000 0.53
2019-03-26 King (Rachel K) Director Buy 22000 0.53
2019-01-30 Glenn (Gregory M) Officer Buy 13168 0.88
2018-07-30 Glenn (Gregory M) Officer Buy 13007 0.88
2018-05-13 Glenn (Gregory M) Officer Buy 19900 1.64
2018-05-13 Glenn (Gregory M) Officer Buy 100 1.64
2018-05-13 Trizzino (John J) Chief Financial Officer Buy 50000 1.64
2018-05-13 Erck (Stanley C) Chief Executive Officer Buy 100000 1.65
2018-01-30 Glenn (Gregory M) Officer Buy 12784 0.88
2017-11-08 Glenn (Gregory M) Officer Buy 10000 1.13
2017-11-08 Erck (Stanley C) Chief Executive Officer Buy 100000 1.13
2017-08-30 Young (James Francis Ph.D.) Director Sell 175000 1.06

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Jackson National Asset Management LLC 317619 0.07% -405568 -56.08% 2019-07-31
Charles Schwab Investment Management Inc 130167 0.55% -100063 -43.46% 2019-07-31
Panagora Asset Management Inc 3114566 0.66% 1674712 116.31% 2019-03-31
State Street Global Advisors 195733 0.83% -- -- 2019-07-31
Fidelity Management & Research Company 1782847 1.38% 267272 17.64% 2019-07-31
Northern Trust Investments Inc 447055 1.63% 17336 4.03% 2019-07-31
Vanguard Investments Australia Ltd 562821 2.40% 559055 14844.80% 2019-07-31
BlackRock Fund Advisors 1040863 4.43% 576 0.06% 2019-07-31
Vanguard Group Inc 2463289 4.75% 303300 14.04% 2019-07-31
BlackRock 123325 0.53% 12191 10.97% 2019-07-31
Teachers Advisors LLC 104474 0.45% 104474 -- 2019-07-31
BlackRock Institutional Trust Company NA 85593 0.36% -97272 -53.19% 2019-07-31
Lincoln Investment Advisors Corporation 21661 0.09% 21661 -- 2019-07-31
Tekla Capital Management LLC 571000 0.12% 571000 -- 2019-07-31
Merchbanc SGIIC 800000 0.17% -200000 -20.00% 2019-07-31
Nomura Asset Management Co Ltd 1173100 0.25% 1173100 -- 2019-07-31
AXA Equitable Funds Management Group, LLC 61980 0.26% -82620 -57.14% 2019-07-31
Taylor Wealth Management Partners 1239895 0.26% -12000 -0.96% 2019-03-31
Vanguard 1248324 0.28% -1778221 -58.75% 2019-07-31
Pictet Asset Management Ltd 1541307 0.33% -6365 -0.41% 2019-07-31
Bellevue Asset Management AG 8330000 1.77% -- -- 2019-06-30
BB Biotech AG 8330000 1.77% -- -- 2018-12-31
Geode Capital Management, LLC 10212244 2.18% 5558285 119.43% 2018-12-31
State Street Corporation 14719594 3.14% -2658231 -15.30% 2018-12-31
BlackRock Inc 32300297 6.88% 77756 0.24% 2018-12-31
Northern Trust Investments N A 4569360 0.97% -9460 -0.21% 2018-12-31
Morgan Stanley - Brokerage Accounts 4018877 0.86% 538464 15.47% 2018-12-31
Northern Trust Corp 4569360 0.97% -9460 -0.21% 2018-12-31
Two Sigma Investments LLC 3282564 0.70% 2268080 223.57% 2018-12-31
Rock Springs Capital Management LP 3250000 0.69% -- -- 2018-12-31
Millennium Management LLC 2934275 0.63% 1645934 127.76% 2018-12-31
Citigroup Inc 1716495 0.37% 723948 72.94% 2018-12-31
BlackRock Asset Management Canada Ltd 445328 1.90% -129 -0.03% 2019-05-31
Bank of New York Mellon Corp 1813020 0.39% 204 0.01% 2018-12-31
Fidelity Management and Research Company 3000393 0.64% -1290492 -30.08% 2018-12-31
FMR Inc 3000393 0.68% -1290492 -30.08% 2018-12-31
Franklin Advisers, Inc. 4691365 1.06% -1020400 -17.86% 2018-12-31
Franklin Resources Inc 4691365 1.06% -1020400 -17.86% 2018-12-31
Baker Bros Advisors LP 4718318 1.07% -- -- 2018-12-31
J.P. Morgan Securities Inc 4103130 0.93% 1543239 60.29% 2018-09-30
JPMorgan Chase & Co 6236458 1.41% 1674958 36.72% 2018-09-30
SSGA Funds Management Inc 7646054 1.99% -43820 -0.57% 2019-02-28
Fidelity SelectCo, LLC 4255172 1.11% -162413 -3.68% 2018-12-31
Morgan Stanley & Co Inc 6187488 1.62% 3596157 138.78% 2018-06-30
Renaissance Technologies Corp 5786464 1.51% 2970899 105.52% 2018-03-31
State Street Corp 23307696 6.11% -1923889 -7.62% 2018-06-30
Franklin Advisers Inc 5711765 1.50% -- -- 2018-06-30
Columbia Mangmt Investment Advisers, LLC 2140080 0.56% -400 -0.02% 2018-06-30
J.P. Morgan Investment Management Inc 1888420 0.49% -123153 -6.12% 2018-06-30
Wellington Management Company LLP 1408301 0.37% 1338017 1903.73% 2018-06-30
UBS Securities LLC 1611084 0.46% 1348341 513.18% 2018-03-31
Deutsche Bank AG 4575682 1.32% 2124200 86.65% 2018-03-31
Credit Suisse First Boston (CSFB) 1344482 0.39% 43473 3.34% 2018-03-31
Jacobs Levy Equity Management, Inc. 1072212 0.31% -517425 -32.55% 2018-03-31
Citadel Advisors Llc 1438501 0.45% 1325342 1171.22% 2017-12-31
Northern Trust Asset Management 753775 0.20% 6440 0.86% 2018-01-31
D. E. Shaw & Co LP 5509639 1.90% 657935 13.56% 2017-06-30
GSA Capital Partners LLP 1690153 0.58% 471347 38.67% 2017-06-30
Chicago Equity Partners LLC 1068300 0.34% -541765 -33.65% 2017-09-30
Group One Trading, LP 1120150 0.41% 1022110 1042.54% 2016-09-30
NorthPointe Capital LLC 1666893 0.61% -457142 -21.52% 2016-09-30
Eventide Asset Management, LLC 2179700 0.80% -- -- 2016-09-30
First Trust Advisors L.P. 3590680 1.32% -1657500 -31.58% 2016-09-30
Invesco PowerShares Capital Mgmt LLC 6184315 2.28% -1720308 -21.76% 2016-09-30
BlackRock, Inc. 19132102 4.00% 158605126 0.10% 1999-11-30
FMR LLC 28902866 4.00% 239604759 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
NT R2000 Value Index Fund - Non-Lending 49463 0.21% -1 -- 2019-06-30
Vanguard Total Stock Market Index Fund 559077 2.38% 559077 -- 2019-06-30
iShares Russell 2000 ETF 511968 2.18% 1001 0.20% 2019-07-30
Vanguard Extended Market Index Fund 316444 1.35% 672 0.21% 2019-06-30
iShares Nasdaq Biotechnology ETF 234053 1.00% -696 -0.30% 2019-07-30
iShares Russell 2000 Value ETF 138929 0.59% 282 0.20% 2019-07-31
State Street Russell Small Cap 80566 0.34% -- -- 2019-06-30
State Street Russell Small/Mid Cap 79150 0.34% -- -- 2019-06-30
iShares Russell 2000 Growth ETF 77426 0.33% -- -- 2019-07-30
NT R2000 Index Fund - NL 75858 0.32% 2734 3.74% 2019-06-30
Vanguard Strategic Small Cap Equity Fund 1419668 0.30% -240712 -14.50% 2018-12-31
CREF Stock Account 53834 0.23% 53834 -- 2019-05-31
Northern Trust Russell 2000 Index DC NL 57589 0.25% 1519 2.71% 2019-06-30
Nomura World Genome Tech Open Mother 1173100 0.25% 1173100 -- 2018-11-19
iShares Micro-Cap ETF 59415 0.25% -- -- 2019-07-30
Vanguard Health Care Index Fund 60687 0.26% -650 -1.06% 2019-06-30
Fidelity 1358283 0.29% 212083 18.50% 2019-01-31
Schwab US Small-Cap ETF 70177 0.30% 60 0.09% 2019-07-31
Pictet-Biotech 1541307 0.33% -6365 -0.41% 2018-09-30
iShares US Small Cap ETF (CAD-Hedged) 393208 1.68% -657 -0.17% 2019-05-30
Vanguard Explorer Fund 936727 0.20% -1230684 -56.78% 2018-12-31
JPMorgan US Small Company Fund 1574700 0.34% -39900 -2.47% 2019-02-28
SPDR 7316011 1.90% -44700 -0.61% 2019-02-28
Schwab Small Cap Index Fund 753795 0.20% 18203 2.47% 2019-01-31
Merchfondo FI 800000 0.21% -200000 -20.00% 2019-01-31
Franklin Biotechnology Discovery Fund 1855362 0.48% -427138 -18.71% 2018-12-31
Fidelity Advisor 995321 0.26% -- -- 2018-11-30
Columbia Small Cap Value Fund I 1135640 0.30% 10500 0.93% 2018-11-30
Vanguard Extended Market Idx Inv 5052410 1.32% 71020 1.43% 2018-07-31
Fidelity Spartan 651621 0.17% 29122 4.68% 2018-04-30
Vanguard VIF Small Co Gr 764712 0.20% 764712 -- 2018-06-30
State Street Russell Small/Mid Cap Idx Fd Cl I 973201 0.34% 24635 2.60% 2017-06-30
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 925520 0.24% -1171 -0.13% 2018-07-31
Columbia Small Cap Value Fund I A 1111140 0.29% 45300 4.25% 2018-07-31
iShares Micro-Cap 1011650 0.25% -- -- 2018-09-12
Vanguard Strategic Small-Cap Equity Inv 1338810 0.35% 351063 35.54% 2018-06-30
JPMorgan US Small Company Instl 1735100 0.45% 34100 2.00% 2018-07-31
iShares Russell 2000 Growth 1542890 0.38% -1488 -0.10% 2018-09-12
Vanguard Explorer Inv 1720481 0.45% 1720481 -- 2018-06-30
Franklin Biotechnology Discovery A 2282500 0.60% -- -- 2018-07-31
iShares Russell 2000 Value 2248918 0.55% -- -- 2018-09-12
iShares Nasdaq Biotechnology 4318864 1.06% -8220 -0.19% 2018-09-12
Vanguard Total Stock Mkt Idx 9290836 2.43% -- -- 2018-07-31
JNL Multi-Manager Small Cap Value A 662170 0.19% 87000 15.13% 2018-03-31
Schwab Small Cap Index 710921 0.19% 138400 24.17% 2018-06-30
CREF Stock R1 684091 0.18% -- -- 2018-04-30
Vanguard Health Care ETF 697498 0.18% 1 -- 2018-05-31
Columbia VP Small Cap Value 2 611574 0.18% -- -- 2018-03-31
BioShares 564544 0.16% -- -- 2018-04-06
Vanguard Instl Ttl Stk Mkt Idx InstlPls 495224 0.13% -- -- 2018-01-31
Royce Value Trust 550000 0.15% -- -- 2017-12-31
Vanguard Small Cap Index 6082684 2.24% 80344 1.34% 2016-12-31
Vanguard Small Cap Growth Index Inv 3416088 1.26% 41064 1.22% 2016-12-31
Eventide Gilead N 1449700 0.53% -- -- 2016-09-30
Vanguard Capital Value Inv 852396 0.31% 575196 207.50% 2016-09-30
Eventide Healthcare & Life Sciences A 730000 0.27% -- -- 2016-09-30
Northwestern Mutual Ser Small Cap Gr Stk 430896 0.16% 39923 10.21% 2016-09-30
Tekla Life Sciences Investors 358000 0.13% -- -- 2016-09-30
First Trust NYSE Arca Biotech Fund 13347672 5.20% 44492 0.30% 2015-11-19
T. Rowe Price Health Sciences Fund 9318862 3.50% -622252 -6.30% 2015-09-30
PowerShares Dynamic Pharmaceuticals Port 5943799 2.30% -- -- 2015-11-19
T. Rowe Price New Horizons Fund 5046200 1.90% -391400 -7.20% 2015-09-30
Fidelity® OTC Portfolio 4963900 1.80% 2114700 74.20% 2015-09-30
iShares Russell 2000 (AU) 4242269 1.60% -5352 -0.10% 2015-11-19
Vanguard Small Cap Growth Index Fund 3064863 1.10% -53703 -1.70% 2015-10-31
Fidelity Advisor® Biotechnology Fund 2472331 0.90% -- -- 2015-09-30
Fidelity® Advisor Small Cap Opps Fund 2403762 0.90% -726200 -23.20% 2015-07-31
Fidelity® Select Biotechnology Portfolio 15181621 5.60% -- -- 2015-09-30

Michael A. McManus Michael A. McManus is on the board of The Eastern Co., Novavax, Inc., LQ Corp., Inc. and The United States Olympic Endowment. He previously occupied the position of Chairman, President & Chief Executive Officer for Misonix, Inc., President & Chief Executive Officer at Jamcor Pharmaceuticals, Inc., Vice President-Strategic Planning at Pfizer Inc., President & Chief Executive Officer of Home Federal Savings Bank (Rochester, Minnesota), President & Chief Executive Officer at New York Bancorp, Inc., Executive Vice President of MacAndrews & Forbes LLC, Executive Vice President at Pantry Pride, Inc. and Executive Vice President at Revlon, Inc. Michael A. McManus received an undergraduate degree from the University of Notre Dame and a graduate degree from Georgetown University Law Center.
James F. Young Currently, James F. Young is Chairman for Novavax, Inc. He is also on the board of 3-V Biosciences, Inc. and CannaRoyalty Corp. In the past he was Chairman at La Jolla Capital, Inc., Chairman, Chief Executive & Financial Officer at Targeted Microwave Solutions, Inc., President-Research & Development at MedImmune LLC, Director-Molecular Genetics Department at Smith Kline & French Laboratories Ltd. and Faculty Member at Icah School of Medicine at Mount Sinai. James F. Young received a doctorate from Baylor College of Medicine and an undergraduate degree from Villanova University.
Gary C. Evans Founder of 7 different companies, including: Magnum Hunter Resources, Inc., Blue Ridge Mountain Resources, Inc. and GreenHunter Resources, Inc. Gary C. Evans is an entrepreneur and businessperson who has been at the head of 15 different companies and presently occupies the position of Chairman & Chief Executive Officer of Energy Hunter Resources, Inc., Chairman & Chief Executive Officer for Eureka Midstream LLC, Chief Executive Officer for PRC Williston LLC and Chief Executive Officer & Director at NGAS Resources, Inc. Mr. Evans is also on the board of Novavax, Inc. (former Lead Independent Director) and Maguire Energy Institute and Principal at Global Hunter Holdings LP. In the past Mr. Evans held the position of Chairman, President & Chief Executive Officer at GreenHunter Resources, Inc. (he founded the company in 2005) and Chief Executive Officer at GreenHunter Water LLC (a subsidiary of GreenHunter Resources, Inc.), Vice President & Manager-Energy Division at Mercantile Bank of Canada, Chairman & Chief Executive Officer at Hunter Resources, Inc. (he founded the company in 1985), Chairman & Chief Executive Officer for Blue Ridge Mountain Resources, Inc. (he founded the company in 2009), Chairman, President & CEO at Magnum Hunter Resources, Inc. (he founded the company in 2005), Chairman & Chief Executive Officer for Magnum Hunter Production, Inc. (he founded the company), Chairman & Chief Executive Officer for Gruy Petroleum Management Co., Chairman of Petro Resources Corp., Chief Executive Officer at Eureka Midstream Holdings LLC (he founded the company in 2014) and Credit Manager & Credit Officer at National Bank of Commerce (Lake Charles, Louisiana).
Iksung Cho Iksung Cho is Vice President-Biostatistics at Novavax, Inc. He previously occupied the position of Principal at MedImmune Vaccines, Inc., Principal at Merck Research Laboratories and Vice President-Biostatistics at MedImmune LLC. Mr. Cho received a graduate degree from Virginia Polytechnic Institute & State University.
Kathleen Callahan Kathleen Callahan is Vice President-Regulatory Affairs at Novavax, Inc. Ms. Callahan received an undergraduate degree from Mount Saint Mary's College and a graduate degree from Hood College.
Stanley C. Erck Currently, Stanley C. Erck occupies the position of President, Chief Executive Officer & Director at Novavax, Inc. He is also on the board of MaxCyte, Inc. (former Director) and MdBio Foundation. Mr. Erck previously held the position of Head-Global Regulatory Affairs Vaccines at Baxter International, Inc., President, Chief Executive Officer & Director at Procept, Inc., President, Chief Executive Officer & Director at Intercell USA, Inc. and Vice President-Corporate Development for Integrated Genetics, Inc. He received an undergraduate degree from the University of Illinois and an MBA from The University of Chicago Booth School of Business.
Gregory M. Glenn Founder of Intercell USA, Inc., Gregory M. Glenn presently is President-Research & Development at Novavax, Inc. In the past Dr. Glenn held the position of Chief Scientific Officer & Senior Vice President at Intercell USA, Inc., Chief Scientific Officer for Intercell AG, Research Scientist at Walter Reed Army Institute of Research and Associate-International Health at Johns Hopkins Bloomberg School of Public Health. Gregory M. Glenn received an undergraduate degree from Whitman College and a doctorate from Oral Roberts University.
Russell P. Wilson Presently, Russell P. Wilson is Senior Vice President-Business Development for Novavax, Inc. In his past career he occupied the position of Chief Financial Officer & Vice President at Supernus Pharmaceuticals, Inc., Chief Financial Officer, Secretary & Senior VP at Intercell USA, Inc. and General Counsel for North American Vaccine, Inc. He received an MBA and a graduate degree from the University of Virginia and an undergraduate degree from Princeton University.
Mervyn L. Hamer Mervyn L. Hamer is Vice President-Manufacturing at Novavax, Inc. In his past career he occupied the position of Vice President-Operations for Intercell USA, Inc. Mr. Hamer received an undergraduate degree from Worcester Polytechnic Institute.
Rachel K. King Rachel K. King founded GlycoMimetics, Inc. Currently, she is President, Chief Executive Officer & Director at this company. Ms. King is also on the board of 6 other companies. Ms. King previously occupied the position of Principal at Bain & Co., Inc., Executive at NEA Management Co. LLC, Chief Executive Officer at Genetic Therapy, Inc., Senior Vice President of Novartis Corp. and Executive Vice President of ALZA Corp. She received an undergraduate degree from Dartmouth College and an MBA from Harvard Business School.
Louis F. Fries Presently, Louis F. Fries is Chief Medical Officer & Senior Vice President at Novavax, Inc. In the past he occupied the position of Vice President-Clinical & Regulatory Affairs at Intellivax, Inc., Director-Clinical Development at Nabi Biopharmaceuticals, Director-Clinical Development at Univax Biologics, Inc. and Vice President-Clinical Affairs at ID Biomedical Corp. Dr. Fries received a doctorate from Duke University and an undergraduate degree from The Johns Hopkins University.
John J. Trizzino John J. Trizzino is CFO, Treasurer, Chief Business Officer & Senior VP at Novavax, Inc. In the past Mr. Trizzino was Chief Executive Officer & Director at IMV, Inc., Vice President-Business Development of Henry Schein, Inc., Senior Vice President-Business Development at Novavax, Inc., Vice President-Business Development of ID Biomedical Corp. and Vice President-Vaccine Franchise at MedImmune LLC. Mr. Trizzino received an undergraduate degree from Long Island University and an MBA from The Leonard N Stern School of Business.
Richard H. Douglas Richard H. Douglas occupies the position of Chairman at Aldeyra Therapeutics, Inc. He is also on the board of Novavax, Inc., MaxCyte, Inc. and Intercell USA, Inc. In the past he occupied the position of Director-New Product Development at Integrated Genetics, Inc. and Senior Vice President-Corporate Development of Genzyme Corp. Dr. Douglas received a doctorate from the University of California, Berkeley and an undergraduate degree from the University of Michigan.
Rajiv Indravadan Modi Rajiv Indravadan Modi is Chairman & Managing Director at Cadila Pharmaceuticals Ltd. Dr. Modi is also Chairman-Governors Board at Indian Institute of Technology Guwahati, Member of American Society for Microbiology, Member of The Genetics Society of America and Member of New York Academy of Sciences and on the board of 19 other companies. In the past Dr. Modi held the position of Council Chairman at Confederation of Indian Industry (Gujarat). Dr. Modi received an undergraduate degree from Indian Institute of Technology Bombay, a doctorate from the University of Michigan and a graduate degree from University College London.
Iksung Cho Iksung Cho is Vice President-Biostatistics at Novavax, Inc. He previously occupied the position of Principal at MedImmune Vaccines, Inc., Principal at Merck Research Laboratories and Vice President-Biostatistics at MedImmune LLC. Mr. Cho received a graduate degree from Virginia Polytechnic Institute & State University.
Timothy Jon Hahn Timothy Jon Hahn is Senior VP-Global Manufacturing Operations at Novavax, Inc. In his past career Dr. Hahn occupied the position of Vice President-Antibody & Vaccine Manufacturing at MedImmune LLC. Dr. Hahn received a graduate degree and a doctorate from Stanford University and an undergraduate degree from Lehigh University.
John A. Herrmann John A. Herrmann holds the position of Secretary, Senior Vice President & General Counsel of Novavax, Inc. In the past Mr. Herrmann occupied the position of Deputy General Counsel at Gene Logic, Inc., Secretary & General Counsel for Ore Pharmaceuticals, Inc., Senior Business Counsel at Celera Group and Senior Corporate Counsel at Baxter Healthcare Corp. He received a graduate degree from the University of Illinois and an undergraduate degree from Brown University.
Amy B. Fix Presently, Amy B. Fix holds the position of Senior Vice President-Regulatory Affairs at Novavax, Inc. In the past she was Senior Director-Regulatory Affairs at Emergent BioSolutions, Inc. She received a graduate degree from the University of Virginia, an MBA from The Johns Hopkins University and an undergraduate degree from the University of Illinois.
Cynthia N. Oliver Cynthia N. Oliver is Senior VP-Process Development Operations at Novavax, Inc. She received a doctorate from The Johns Hopkins University, a graduate degree from the University of Massachusetts and an undergraduate degree from Connecticut College.
John J. Trizzino John J. Trizzino is CFO, Treasurer, Chief Business Officer & Senior VP at Novavax, Inc. In the past Mr. Trizzino was Chief Executive Officer & Director at IMV, Inc., Vice President-Business Development of Henry Schein, Inc., Senior Vice President-Business Development at Novavax, Inc., Vice President-Business Development of ID Biomedical Corp. and Vice President-Vaccine Franchise at MedImmune LLC. Mr. Trizzino received an undergraduate degree from Long Island University and an MBA from The Leonard N Stern School of Business.
Jill Hoyt Jill Hoyt holds the position of Vice President-Human Resources at Novavax, Inc. Ms. Hoyt received an undergraduate degree from Shepherd University and a graduate degree from Marymount University.
Brian Rosen Brian Rosen occupies the position of Senior Vice President-Commercial Strategy at Novavax, Inc. Mr. Rosen is also Chairman at MdBio Foundation. In his past career Mr. Rosen was Chief Policy, Advocacy & Patient Access Officer at The Leukemia & Lymphoma Society. Mr. Rosen received an undergraduate degree from Tufts University and a graduate degree from Maurice A. Deane School of Law at Hofstra University.
Andrea N. Flynn Dr. Andrea N. Flynn is a Senior Director-IR & Communications at Array BioPharma, Inc. and a Director-Investor & Media Relations at Novavax, Inc.
Brian Rosen Brian Rosen occupies the position of Senior Vice President-Commercial Strategy at Novavax, Inc. Mr. Rosen is also Chairman at MdBio Foundation. In his past career Mr. Rosen was Chief Policy, Advocacy & Patient Access Officer at The Leukemia & Lymphoma Society. Mr. Rosen received an undergraduate degree from Tufts University and a graduate degree from Maurice A. Deane School of Law at Hofstra University.
Jody Lichaa Jody Lichaa is Senior Vice President-Quality Assurance at Novavax, Inc. Ms. Lichaa received an undergraduate degree from Northeastern University.
Iksung Cho Iksung Cho is Vice President-Biostatistics at Novavax, Inc. He previously occupied the position of Principal at MedImmune Vaccines, Inc., Principal at Merck Research Laboratories and Vice President-Biostatistics at MedImmune LLC. Mr. Cho received a graduate degree from Virginia Polytechnic Institute & State University.
Shiva G. Fritsch Presently, Shiva G. Fritsch is Senior Vice President-Human Resources of REGENXBIO, Inc. She is also Senior Director-Talent Management at Novavax, Inc. Ms. Fritsch received an MBA from Robert H. Smith School of Business and an undergraduate degree from Bryn Mawr College.
Chris Dunne Chris Dunne is Vice President-Finance at Novavax, Inc.
Erika Trahan Currently, Erika Trahan occupies the position of Senior Manager-Investor & Public Relations at Novavax, Inc.

量化对比

全部评论 165

  • 【摩根大通投资者调查显示Moderna和Novavax成做空首选】摩根大通对80家对冲基金和专业投资者的调查显示,Moderna和Novavax已经走完了上行的道路,是他们押注今年将下跌的主要候选者。这两家疫苗制造商是他们打算在2021年做空的生物科技股头两位。尽管去年Novavax和Moderna的涨幅高达2700%和434%,但许多空头仍一心瞄准这些生物科技公司。最近散户购买狂潮消退,可能意味着做空这两家公司的对冲基金最终可能会收获回报。摩根大通的调查中,其他首选做空股还包括Beam Therapeutics Inc.以及Biogen Inc.。

  • 【摩根大通投资者调查显示Moderna和Novavax成做空首选】摩根大通对80家对冲基金和专业投资者的调查显示,Moderna和Novavax已经走完了上行的道路,是他们押注今年将下跌的主要候选者。这两家疫苗制造商是他们打算在2021年做空的生物科技股头两位。尽管去年Novavax和Moderna的涨幅高达2700%和434%,但许多空头仍一心瞄准这些生物科技公司。最近散户购买狂潮消退,可能意味着做空这两家公司的对冲基金最终可能会收获回报。摩根大通的调查中,其他首选做空股还包括Beam Therapeutics Inc.以及Biogen Inc.。

  • 【摩根大通投资者调查显示:Moderna和Novavax成做空首选】在一些华尔街投资者的眼中,Moderna Inc.和Novavax Inc.已经走完了上行的道路,是他们押注今年将下跌的主要候选者。在摩根大通对80家对冲基金和专业投资者的调查中,这两家疫苗制造商是他们打算在2021年做空的生物科技股头两位。摩根大通的调查中,其他首选做空股还包括Beam Therapeutics Inc.以及Biogen Inc.。

  • 【摩根大通投资者调查显示:Moderna和Novavax成做空首选】在一些华尔街投资者的眼中,Moderna Inc.和Novavax Inc.已经走完了上行的道路,是他们押注今年将下跌的主要候选者。在摩根大通对80家对冲基金和专业投资者的调查中,这两家疫苗制造商是他们打算在2021年做空的生物科技股头两位。摩根大通的调查中,其他首选做空股还包括Beam Therapeutics Inc.以及Biogen Inc.。

  • 美股抗疫概念股走强,Equillium涨超15%,Moderna涨超7%,Vir Biotechnology涨近6%,BioNTech SE、诺瓦瓦克斯医药涨近5%。

  • 诺瓦瓦克斯医药短线拉升,跌幅缩窄至5%。

  • 诺瓦瓦克斯医药(NVAX.O)盘前跌3.1%,据悉公司推迟与欧盟签署新冠疫苗供应协议。

  • 市场消息:诺瓦瓦克斯医药已开始在印度的新冠疫苗试验。

  • 诺瓦瓦克斯医药盘中上扬,现涨超10%。

  • 美国抗疫概念股盘初走高,诺瓦瓦克斯医药涨6.7%,Moderna涨4.5%,阿斯利康涨3.3%,BioNTech SE涨1.4%。

  • 诺瓦瓦克斯医药:预计首剂美国加强剂疫苗将在年底上市。

  • 诺瓦瓦克斯医药:预计首剂美国加强剂疫苗将在年底上市。

  • 【美股盘前消息速报】①美国股指期货周五盘前涨跌互现,因美国10年期国债收益率再度上攻,且回到1.6%上方。截至发稿,道指期货涨0.3%,标普500期指跌0.3%,纳指期货跌1.3%。②欧洲斯托克600指数下跌0.5%,英国富时100指数上涨0.1%,法国CAC40指数下跌0.1%,德国DAX30指数下跌0.6%。③在美国债市再度暴动之际,美元趁机上涨,逼近92关口,结束三连跌。④现货黄金延续早前跌势,一度跌穿1700关口,最低触及1699.04美元/盎司,日内最多更是暴跌近30美元。⑤美国股市在过去几天一直在上涨,从板块来看,美股大型科技股盘前全线下跌,哔哩哔哩跌超4%,京东跌3.5%,百度跌5.4%,推特跌3.8%,苹果公司跌1.7%,谷歌跌1.5%,微软公司跌1.3%,亚马逊跌1.3%。⑥新能源汽车股盘前全线下跌,小鹏汽车盘前跌7.2%,蔚来跌5.7%,百度跌5.4%,理想汽车跌5%,特斯拉跌3.8%。⑦芯片股盘前全线下跌,台积电盘前跌2.6%,美光科技跌2.3%,超威半导体跌2%,英伟达跌1.9%,应用材料跌1.7%。⑧区块链板块盘前下挫,嘉楠科技跌超10%,Bit Digital跌7.6%,Marathon Patent跌6.7%,Riot Blockchain跌5.2%。⑨特斯拉跌4.2%,特斯拉和塔塔集团就在印度建设充电设施进行合作。⑩Verizon拟发行7.5亿美元2026年到期的浮动利率票据,17.5亿美元2024年到期的票面利率0.75%的票据。⑪诺瓦瓦克斯医药盘前涨22%,其新冠疫苗于英国第三阶段试验显示有效性为96.4%。⑫Poshmark盘前大跌11%,全年净利润低于市场预期。⑬DocuSign盘前跌4.5%,2021财年净亏损扩大,差于市场预期。⑭波音表示,投资公司777 PARTNERS订购了24架波音737 MAX飞机。⑮阿里巴巴盘前跌近3%,胡晓明辞任蚂蚁金服 CEO。⑯百度跌5.4%,百度今日起招股,百度目前孖展暂录339.8亿港元,超额认购逾23倍。⑰花旗将京东目标价上调至120美元,评级买入。

  • 【美股盘前消息速报】①美国股指期货周五盘前涨跌互现,因美国10年期国债收益率再度上攻,且回到1.6%上方。截至发稿,道指期货涨0.3%,标普500期指跌0.3%,纳指期货跌1.3%。②欧洲斯托克600指数下跌0.5%,英国富时100指数上涨0.1%,法国CAC40指数下跌0.1%,德国DAX30指数下跌0.6%。③在美国债市再度暴动之际,美元趁机上涨,逼近92关口,结束三连跌。④现货黄金延续早前跌势,一度跌穿1700关口,最低触及1699.04美元/盎司,日内最多更是暴跌近30美元。⑤美国股市在过去几天一直在上涨,从板块来看,美股大型科技股盘前全线下跌,哔哩哔哩跌超4%,京东跌3.5%,百度跌5.4%,推特跌3.8%,苹果公司跌1.7%,谷歌跌1.5%,微软公司跌1.3%,亚马逊跌1.3%。⑥新能源汽车股盘前全线下跌,小鹏汽车盘前跌7.2%,蔚来跌5.7%,百度跌5.4%,理想汽车跌5%,特斯拉跌3.8%。⑦芯片股盘前全线下跌,台积电盘前跌2.6%,美光科技跌2.3%,超威半导体跌2%,英伟达跌1.9%,应用材料跌1.7%。⑧区块链板块盘前下挫,嘉楠科技跌超10%,Bit Digital跌7.6%,Marathon Patent跌6.7%,Riot Blockchain跌5.2%。⑨特斯拉跌4.2%,特斯拉和塔塔集团就在印度建设充电设施进行合作。⑩Verizon拟发行7.5亿美元2026年到期的浮动利率票据,17.5亿美元2024年到期的票面利率0.75%的票据。⑪诺瓦瓦克斯医药盘前涨22%,其新冠疫苗于英国第三阶段试验显示有效性为96.4%。⑫Poshmark盘前大跌11%,全年净利润低于市场预期。⑬DocuSign盘前跌4.5%,2021财年净亏损扩大,差于市场预期。⑭波音表示,投资公司777 PARTNERS订购了24架波音737 MAX飞机。⑮阿里巴巴盘前跌近3%,胡晓明辞任蚂蚁金服 CEO。⑯百度跌5.4%,百度今日起招股,百度目前孖展暂录339.8亿港元,超额认购逾23倍。⑰花旗将京东目标价上调至120美元,评级买入。

  • H.C.Wainwright:将诺瓦瓦克斯医药目标价从207美元上调至317美元。

  • 诺瓦瓦克斯医药(NVAX.O)盘前涨22%,其新冠疫苗于英国第三阶段试验显示有效性为96.4%。

  • 美股抗疫概念股涨幅居前,Vir Biotechnology(VIR.O)涨近30%,诺瓦瓦克斯医药(NVAX.O)涨超5%,BioNTech SE(BNTX.O)涨超3%,Moderna(MRNA.O)涨近2%。

  • 诺瓦瓦克斯医药(NVAX.O)盘中涨超10%,报174美元。

  • 诺瓦瓦克斯医药(NVAX.O)跌幅扩大至15%,现报155.01美元。

  • 抗疫概念股跌幅居前,Vir Biotechnology(VIR.O)跌超31%,Moderna(MRNA.O)跌超8%,Vaxart(VXRT.O)跌7.7%,Inovio制药(INO.O)跌超5%,诺瓦瓦克斯医药(NVAX.O)跌3.47%。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐